Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Axial Spondyloarthritis (SELECT-AXIS 2)
NCT04169373Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by AbbVie Inc. Primary endpoint: Assessment of SpondyloArthritis International Society 40 Response at 14 weeks. Started Nov 2019; status: completed.
02
Drugs
upadacitinib
03
Conditions
ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT04169373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169373.